Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Clinical Decision-Making for Patients With HR+ HER2- Early Breast Cancer
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: July 9, 2021 Expiration: July 8, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Sara Tolaney, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Appraise current/emerging published data and consensus-based guidelines to inform the use of biomarkers and genomic classifiers to assess risk of recurrence
  • Individualize the selection of systemic therapy for appropriate patients with HR+/HER2- EBC to include CDK4/6 inhibitors with or without endocrine therapy
  • Develop strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to support quality of life and continuation of care
  • Identify patients with HR+/HER2- EBC eligible for enrollment on ongoing clinical studies investigating novel therapies

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Sara Hurvitz, MD, FACP

Professor of Medicine
Director,
Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Daiichi Sankyo, Dignitana, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, OBI, Pfizer, Phoenix Molecular Designs, Pieris, Puma, Radius, Sanofi, Seattle Genetics, and Zymeworks.
Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director,
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Joyce O’Shaughnessy, MD, has disclosed that she has received consulting fees from AbbVie, Agendia, Amgen, Aptitude, AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, G1 Therapeutics, Genentech, Immunomedics, Ipsen, Jounce, Lilly, Merck, Myriad, Novartis, Odonate, Pfizer, Puma, Prime, Roche, Seattle Genetics, and Syndax.
Sara Tolaney, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women's Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician

Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support (paid to her institution) from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech, Immunomedics/Gilead Sciences, Lilly, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, Seattle Genetics and has received consulting fees from 4D Pharma, AstraZeneca, Athenex, Bristol-Myers Squibb, Celldex, Certara, Chugai, CytomX, Daiichi Sankyo, Eisai, Ellipses Pharma, G1 Therapeutics, Genentech, Immunomedics/Gilead Sciences, Kyowa Kirin, Lilly, Mersana, Nanostring, Nektar, Novartis, Odonate, OncoPep, OncoSec, Pfizer, Puma, Sanofi, Samsung Bioepsis, Seattle Genetics, and Silverback.

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Shara Pantry, PhD
Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with breast cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners in selecting individualized treatment for patients with HR+/HER2- early-stage breast cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 09, 2021, through July 08, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Clinical Decision-Making for Patients With HR+ HER2- Early Breast Cancer
  • CME

Loading...
Learn from the experts how to assess recurrence risk, incorporate CDK4/6 inhibitor–based therapy, and manage treatment-related adverse events for patients with HR+/HER2- early breast cancer in this on-demand webcast from a live webinar.
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Sara Tolaney, MD, MPH
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: July 9, 2021 Expiration: July 8, 2022

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Interactive online tool with strategies to assess and manage AEs associated with oral targeted therapy for HR+, HER2– breast cancer, from Clinical Care Options

Donna M. Fitzgerald, PA-C, MPAS Matthew P. Goetz, MD Marissa Marti, APRN, AGNP-C, AOCNP Joyce O'Shaughnessy, MD Laura M. Spring, MD Released: September 14, 2021

Downloadable slideset with the latest expert insights on CDK4/6 inhibitors for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: August 24, 2021

Key takeaways from international and US experts on CDK4/6 inhibitors for HR+/HER2- early breast cancer, from Clinical Care Options (CCO)

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Released: August 17, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue